Pfizer Inc. 8K -

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 28, 2011

PFIZER INC.
(Exact name of registrant as specified in its charter)

Delaware
1-3619
13-5315170
(State or other Jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

235 East 42nd Street
New York, New York
(Address of principal executive offices)

  
10017
(Zip Code)

Registrant's telephone number, including area code:

(212) 733-2323

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

[   ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 5.07

Submission of Matters to a Vote of Security Holders
(a) Pfizer’s Annual Meeting of Shareholders was held on April 28, 2011.
 
(b) Shareholders voted on the matters set forth below.

1.  The nominees for election to the Board of Directors were elected, each for a one-year term, based upon the following votes:

Nominee
Votes For
   Votes Against
  Abstentions
     Broker Non-Votes

Dennis A. Ausiello
5,479,523,804
63,025,888
22,031,093
1,029,664,119

Michael S. Brown
5,451,874,773
90,844,187
21,869,298
1,029,664,119

M. Anthony Burns
5,443,824,812
97,791,397
22,971,788
1,029,664,119

W. Don Cornwell
5,170,584,487
364,270,650
29,733,058
1,029,664,119
Frances D. Fergusson
5,214,218,269
328,167,848
22,190,916
1,029,664,119

William H. Gray III
5,385,867,075
156,525,332
22,157,653
1,029,664,119

Constance J. Horner
5,446,823,844
95,839,667
21,890,460
1,029,664,119

James M. Kilts
5,168,196,717
374,127,871
22,229,874
1,029,664,119

George A. Lorch
5,408,148,441
133,916,369
22,488,657
1,029,664,119

John P. Mascotte
5,478,842,805
63,657,172
22,087,732
1,029,664,119

Suzanne Nora Johnson
5,208,605,967
333,835,141
22,109,895
1,029,664,119

Ian C. Read
5,470,406,623
71,686,601
22,406,881
1,029,664,119

Stephen W. Sanger
5,478,015,822
63,584,358
22,950,583
1,029,664,119

2.  The proposal to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for 2011 was approved based upon the following votes:

Votes for approval
6,502,916,982
  
Votes against
64,467,907
  
  Abstentions
26,867,070
  
Broker Non-Votes
N/A
  
   

3. The proposal to approve, on an advisory basis, executive compensation was approved based upon the following votes:

 

 
Votes for approval
3,082,645,956
  
Votes against
2,422,993,133
  
Abstentions
58,948,621
  
Broker-Non Votes
1,029,664,119
  

4.  The proposal on the frequency of future advisory votes on executive compensation received the following votes:

 

 
For 3 Years
703,041,341
  
For 2 Years
1,103,545,026
  
For 1 Year
3,727,445,064
  
Abstentions
30,525,614
  
Broker-Non Votes
1,029,664,119
  
 
See Item 5.07(d) below.
 

5.  The shareholder proposal regarding publication of political contributions was not approved based upon the following votes:

Votes for approval
219,466,804
  
Votes against
4,516,266,497
  
Abstentions
828,838,153
  
Broker non-votes
1,029,664,119


6.   The shareholder proposal regarding public policy initiatives was not approved based upon the following votes:

Votes for approval
179,765,706
  
Votes against
4,578,844,725
  
Abstentions
805,929,786
  
Broker non-votes
1,029,664,119

7.   The shareholder proposal regarding pharmaceutical price restraints was not approved based upon the following votes:

Votes for approval
124,165,830
  
Votes against
4,487,013,964
  
Abstentions
953,366,804
  
Broker non-votes
1,029,664,119

8.   The shareholder proposal regarding action by written consent was not approved based upon the following votes:

Votes for approval
2,632,851,163
  
Votes against
2,878,790,745
  
Abstentions
52,890,306
  
Broker non-votes
1,029,664,119

9.  The shareholder proposal regarding special shareholder meetings was not approved based upon the following votes:

Votes for approval
2,290,530,503
  
Votes against
3,235,353,452
  
Abstentions
38,653,115
  
Broker non-votes
1,029,664,119

10.   The shareholder proposal regarding animal research was not approved based upon the following votes:

Votes for approval
197,481,788
  
Votes against
4,208,648,937
  
Abstentions
1,158,419,810
  
Broker non-votes
1,029,664,119
     
(c) Not applicable.    
 
(d) Based upon the results set forth in item (b) (4) above, the Board of Directors has determined that advisory votes on executive compensation will be submitted to shareholders on an annual basis.

 

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

   
PFIZER INC.
     
   
By: /s/  Matthew Lepore
 Matthew Lepore
   
Title: Vice President & Corporate Secretary, Chief Counsel - Corporate Governance
Dated: May 3, 2011